A review on the role of novel adipokine Isthmin-1 and Subfatin in human type 2 diabetes mellitus
DOI:
https://doi.org/10.32792/utq/utjsci/v10i2.1129Keywords:
Isthmin-1, diabetes mellitus, Subfatin, adipokine, insulin resistanceAbstract
Adipokines are essential for maintaining cardiovascular and metabolic balance. The term "adipokines" refers to peptides in the pancreas, brain, vascular system, liver, immune system and muscle. adipokines regulate numbers of factors, such as energy expenditure, hunger, satiety, insulin sensitivity, and blood pressure, insulin secretion, adipogenesis and fat distribution, and that might make them play a role in future pharmacological treatment strategies for obesity and metabolic diseases. Isthmin-1 (Ism-1) is a recently discovered insulin-like adipokine that suppresses hepatic lipids. According to recent research, Ism-1 can enhance lipid metabolism and treat metabolic disorders linked to type 2 diabetic mellitus (T2DM). The primary source of the protein subfatin (SUB) is white adipose tissue. Subfatin (SUB) is expressed in these following tissues: adipose tissue, brain tissue, thymus gland, liver, activated human monocytes, spleen, omental adipose tissue, muscle, salivary glands and heart tissues. The SUB lowers insulin resistance to control glucose metabolism. Isthmian-1 is a novel biomarker for early management and diagnosis of T2DM and has a beneficial effect in glucose homeostasis and might be therapeutic for diabetes. Subfatin also plays a role in glucose metabolism and insulin sensitivity, so it has significant effect in pathogenesis and complication of diabetes.
References
C. KNAI, M. SUHRCKE, AND T. LOBSTEIN, “OBESITY IN EASTERN EUROPE: AN OVERVIEW OF ITS HEALTH AND ECONOMIC IMPLICATIONS,” ECON. HUM. BIOL., VOL. 5, NO. 3, PP. 392–408, 2007.
M.-E. Piché, A. Tchernof, and J.-P. Després, “Obesity phenotypes, diabetes, and cardiovascular diseases,” Circ. Res., vol. 126, no. 11, pp. 1477–1500, 2020.
C. Cercato and F. Fonseca, "Cardiovascular risk and obesity," Diabetology & metabolic syndrome, vol. 11, no. 1, pp. 1-15, 2019.
L. Liu et al., “Adipokines, adiposity, and atherosclerosis,” Cell. Mol. Life Sci., vol. 79, no. 5, p. 272, 2022.
V. J. Clemente-Suárez et al., “The Role of Adipokines in Health and Disease,” Biomedicines, vol. 11, no. 5, p. 1290, 2023.
S. Metz, L. O. Huang, and T. O. Kilpeläinen, “Genetic variation, adipokines, and cardiometabolic disease,” Curr. Opin. Pharmacol., vol. 52, pp. 33–39, 2020.
T. Farkhondeh et al., “An overview of the role of adipokines in cardiometabolic diseases,” Molecules, vol. 25, no. 21, p. 5218, 2020.
X. Unamuno, J. Gómez‐Ambrosi, A. Rodríguez, S. Becerril, G. Frühbeck, and V. Catalán, “Adipokine dysregulation and adipose tissue inflammation in human obesity,” Eur. J. Clin. Invest., vol. 48, no. 9, p. e12997, 2018.
Z. Wei, Y. Chen, and R. P. Upender, “Sleep Disturbance and Metabolic Dysfunction: The Roles of Adipokines,” Int. J. Mol. Sci., vol. 23, no. 3, p. 1706, 2022.
Z. Jiang et al., “Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis,” Cell Metab., vol. 33, no. 9, pp. 1836–1852, 2021.
M. Hu, X. Zhang, C. Hu, T. Teng, and Q.-Z. Tang, “A brief overview about the adipokine: Isthmin-1,” Front. Cardiovasc. Med., vol. 9, p. 939757, 2022.
J. Heeren and L. Scheja, “Isthmin 1—a novel insulin-like adipokine,” Nat. Rev. Endocrinol., vol. 17, no. 12, pp. 709–710, 2021.
N. Nguyen, S. Xu, T. Y. W. Lam, W. Liao, W. S. F. Wong, and R. Ge, “ISM1 suppresses LPS-induced acute lung injury and post-injury lung fibrosis in mice,” Mol. Med., vol. 28, no. 1, p. 72, 2022.
R. Valle-Rios et al., “Isthmin 1 is a secreted protein expressed in skin, mucosal tissues, and NK, NKT, and th17 cells,” J. Interf. Cytokine Res., vol. 34, no. 10, pp. 795–801, 2014.
V. Sahiri et al., “The Angiogenesis Inhibitor Isthmin-1 (ISM1) Is Overexpressed in Experimental Models of Glomerulopathy and Impairs the Viability of Podocytes,” Int. J. Mol. Sci., vol. 24, no. 3, p. 2723, 2023.
J. Wang et al., “Circulating Ism1 reduces the risk of Type 2 diabetes but not diabetes-associated NAFLD,” Front. Endocrinol. (Lausanne)., vol. 13, p. 890332, 2022.
F. J. Ruiz-Ojeda et al., “Serum levels of the novel adipokine isthmin-1 are associated with obesity in pubertal boys,” World J. Pediatr., pp. 1–9, 2023.
L. O. Farhan, B. A. Abed, and I. N. Salman, “Insulin Like Growth Factor Binding Protein 7 as a Novel Diagnostic Marker in Sera of Iraqi Patients with Acromegaly,” Baghdad Sci. J., vol. 20, no. 3 (Suppl.), p. 979, 2023.
J. Liao et al., “Serum Isthmin-1 Was Increased in Type 2 Diabetic Patients but Not in Diabetic Sensorimotor Peripheral Neuropathy,” Diabetes, Metab. Syndr. Obes., pp. 2013–2024, 2023.
G. J. Kashtl, B. A. Abed, L. O. Farhan, I. Noori, and A. S. D. Salman, "A Comparative Study to Determine LDH Enzyme Levels in Serum Samples of Women with Breast Cancer and Women with Breast Cancer and Type 2 Diabetes Mellitus," J. Med. Chem. Sci, vol. 6, no. 4, pp. 883-890, 2023.
L. Menghuan et al., “Advances in research of biological functions of Isthmin-1,” J. Cell Commun. Signal., pp. 1–15, 2023.
N. U. G. Mohammed, F. M. Khaleel, and F. I. Gorial, “Cystatin D as a new diagnostic marker in rheumatoid arthritis,” Gene Reports, vol. 23, p. 101027, 2021.
D. J. Fazakerley, F. Koumanov, and G. D. Holman, “GLUT4 On the move,” Biochem. J., vol. 479, no. 3, pp. 445–462, 2022.
N. U. G. Mohammed, F. M. Khaleel, and F. I. Gorial, “The Role of Serum Chitinase-3-Like 1 Protein (YKL-40) Level and its Correlation with Proinflammatory Cytokine in Patients with Rheumatoid Arthritis,” Baghdad Sci. J., 2022.
M. A. DeStefano and E. Jacinto, “Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2),” Biochem. Soc. Trans., vol. 41, no. 4, pp. 896–901, 2013.
N. Tzenios, “Obesity as a risk factor for cancer,” EPRA Int. J. Res. Dev., vol. 8, no. 2, pp. 101–104, 2023.
H. J. Hassan, T. U. Mohammad, and E. K. Hameed, “The Elevation of Serum Subfatin Levels in Patients with Double Diabetes,” J. Surv. Fish. Sci., vol. 10, no. 3S, pp. 5479–5487, 2023.
D. Löffler et al., “METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans,” Int. J. Obes., vol. 41, no. 1, pp. 112–119, 2017.
K. Ugur et al., “Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome.,” Eur. Rev. Med. Pharmacol. Sci., vol. 26, no. 6, 2022.
S. Huang, L. Cao, H. Cheng, D. Li, Y. Li, and Z. Wu, “The blooming intersection of subfatin and metabolic syndrome,” Rev. Cardiovasc. Med., vol. 22, no. 3, pp. 799–805, 2021.
H. S. Chung et al., “Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes,” Diabetes Res. Clin. Pract., vol. 136, pp. 100–107, 2018.
J. Y. Bae, “Aerobic exercise increases meteorin-like protein in muscle and adipose tissue of chronic high-fat diet-induced obese mice,” Biomed Res. Int., vol. 2018, 2018.
R. R. Rao et al., “Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis,” Cell, vol. 157, no. 6, pp. 1279–1291, 2014.
A. C. Lehnig and K. I. Stanford, “Exercise-induced adaptations to white and brown adipose tissue,” J. Exp. Biol., vol. 221, no. Suppl_1, p. jeb161570, 2018.
L. O. Farhan, B. A. Abed, and A. Dawood, “Comparison Study between Adipsin Levels in Sera of Iraqi Patients with Diabetes and Neuropathy,” Baghdad Sci. J., vol. 20, no. 3, p. 726, 2023.
B. A. Abed and G. S. Hamid, “Evaluation of Lipocalin-2 and Vaspin Levels in In Iraqi Women with Type 2 Diabetes Mellitus,” Iraqi J. Sci., pp. 4650–4658, 2022.
C. Wang et al., “Serum isthmin-1 levels are positively and independently correlated with albuminuria in patients with type 2 diabetes mellitus,” BMJ Open Diabetes Res. Care, vol. 10, no. 5, p. e002972, 2022.
N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nat. Rev. Immunol., vol. 11, no. 2, pp. 85–97, 2011.
B. H. Goodpaster and L. M. Sparks, “Metabolic flexibility in health and disease,” Cell Metab., vol. 25, no. 5, pp. 1027–1036, 2017.
N. S. Kalehsar and T. Golmohammadi, “Association between serum adiponectin and HDL-C in type II diabetic patients,” Glob. J. Health Sci., vol. 7, no. 2, p. 243, 2015.
L. Osório et al., “ISM1 regulates NODAL signaling and asymmetric organ morphogenesis during development,” J. Cell Biol., vol. 218, no. 7, pp. 2388–2402, 2019.
T. Shimizu, Y. Takahashi, H. Fujita, and H. Waki, “Pick the best of both glucose and lipid metabolism,” J. Diabetes Investig., vol. 13, no. 7, pp. 1132–1133, 2022.
S. E. ATTA and E. D. SALMAN, “Molecular Study of Fluoroquinolones Resistance Staphylococcus Aureus Isolated from Different Clinical Sources.,” Int. J. Pharm. Res., vol. 12, no. 3, 2020.
R. Feng et al., “Serum Isthmin-1 is negatively correlated with HDL-C in type 2 diabetes mellitus,” J. Diabetes Complications, vol. 37, no. 10, p. 108567, 2023.
I. Csige et al., “The impact of obesity on the cardiovascular system,” J. Diabetes Res., vol. 2018, 2018.
M. Dadmanesh, H. Aghajani, R. Fadaei, and K. Ghorban, “Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines,” PLoS One, vol. 13, no. 9, p. e0204180, 2018.
C. M. Kusminski, P. E. Bickel, and P. E. Scherer, “Targeting adipose tissue in the treatment of obesity-associated diabetes,” Nat. Rev. Drug Discov., vol. 15, no. 9, pp. 639–660, 2016.
H. M. El-Ashmawy, F. O. Selim, T. A. M. Hosny, and H. N. Almassry, “Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis,” Diabetes Res. Clin. Pract., vol. 150, pp. 57–63, 2019.
E. Onalan et al., “Low serum levels of meteorin-like/subfatin: an indicator of diabetes mellitus and insulin resistance?,” Endokrynol. Pol., vol. 71, no. 5, pp. 397–403, 2020.
C. Cavli, E. ÖNALAN, B. Yakar, E. DÖNDER, I. Buran, and E. ÖNALAN, “Low serum levels of meteorin-like/subfatin is related to obesity and insulin resistance,” Fam. Pract. Palliat. Care, vol. 7, no. 5, pp. 137–141, 2022.
J. H. Lee et al., “Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes,” Diabetes Res. Clin. Pract., vol. 135, pp. 7–10, 2018.
K. Wang et al., “Serum levels of meteorin-like (Metrnl) are increased in patients with newly diagnosed type 2 diabetes mellitus and are associated with insulin resistance,” Med. Sci. Monit. Int. Med. J. Exp. Clin. Res., vol. 25, p. 2337, 2019.
S. Zheng, Z. Li, J. Song, J. Liu, and C. Miao, “Metrnl: a secreted protein with new emerging functions,” Acta Pharmacol. Sin., vol. 37, no. 5, pp. 571–579, 2016.
Lefta, N. A., Abed, A. Y., A. Abed, B. Estimation of Asprosin Levels in Female Iraqi Patients with Type 2 Diabetes and Hypothyroidism. Journal of Medicinal and Chemical Sciences, 2023; 6(2): 433-439. doi: 10.26655/JMCHEMSCI.2023.2.23.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2023 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
